@article{750df0e32d4c45218b13da31c377a669,
title = "Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta",
abstract = "Background: Susceptibility magnetic resonance imaging (MRI) is sensitive to iron-related changes in the substantia nigra pars compacta (SNc), the key pathologic locus of parkinsonisms. It is unclear, however, if iron deposition in the SNc is associated with its neurodegeneration. Objective: The objective of this study was to test whether susceptibility MRI metrics in parkinsonisms are associated with SNc neuropathologic features of dopaminergic neuron loss, gliosis, and α-synuclein and tau burden. Methods: This retrospective study included 27 subjects with both in vivo MRI and postmortem data. Multigradient echo imaging was used to derive the apparent transverse relaxation rate (R2*) and quantitative susceptibility mapping (QSM) in the SNc. Archived midbrain slides that were stained with hematoxylin and eosin, anti-α-synuclein, and anti-tau were digitized to quantify neuromelanin-positive neuron density, glial density, and the percentages of area occupied by positive α-synuclein and tau staining. MRI-histology associations were examined using Pearson correlations and regression. Results: Twenty-four subjects had postmortem parkinsonism diagnoses (Lewy body disorder, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration), two had only Alzheimer's neuropathology, and one exhibited only mild atrophy. Among all subjects, both R2* and QSM were associated with glial density (r ≥ 0.67; P < 0.001) and log-transformed tau burden (r ≥ 0.53; P ≤ 0.007). Multiple linear regression identified glial density and log-transformed tau as determinants for both MRI metrics (R2 ≥ 0.580; P < 0.0001). Neither MRI metric was associated with neuron density or α-synuclein burden. Conclusions: R2* and QSM are associated with both glial density and tau burden, key neuropathologic features in the parkinsonism SNc.",
author = "Wang, {Ernest W.} and Brown, {Gregory L.} and Lewis, {Mechelle M.} and Jellen, {Leslie C.} and Cunfeng Pu and Johnson, {Melinda L.} and Hairong Chen and Lan Kong and Guangwei Du and Xuemei Huang",
note = "Funding Information: This work was supported by the National Institute of Neurological Disease and Stroke (R01‐NS060722, U01‐NS082151, and U01‐NS112008 to X.H.), the National Institute of Environmental Health Sciences (F30‐ES030607 to E.W.W.; ES019672 to X.H.), the National Institute on Aging (F30‐AG067651 to G.L.B.), the Hershey Medical Center General Clinical Research Center (National Center for Advancing Translational Sciences, UL1‐TR000127), the Penn State Clinical and Translational Science Institute (National Center for Advancing Translational Sciences, TL1‐TR002016), The Michael J. Fox Foundation for Parkinson's Research (18078 to G.D.), and the Penn State Translational Brain Research Center. This study would not be possible without our study participants, their families, our study coordinators, and Ally Lewis of Penn State Decedent Care. Funding Information: Guangwei Du: Received funding from the National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, The Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, and Weston Brain Institute. Funding Information: Mechelle M. Lewis: Received funding from the National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, The Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, Weston Brain Institute, Bristol Myers Squibb, Biohaven, Pfizer, and Department of Defense. Funding Information: Xuemei Huang: Received funding from the National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, The Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Association, Alzheimer's Research UK, Weston Brain Institute, Bristol Myers Squibb, Biohaven, Pfizer, and Department of Defense. Funding Information: Gregory L. Brown: Received funding from the National Institute of Aging. Funding Information: Lan Kong: Received funding from the National Institute of Environmental Health Sciences, National Institute of Neurological Disorders and Stroke, and The Michael J. Fox Foundation for Parkinson's Research. Publisher Copyright: {\textcopyright} 2023 International Parkinson and Movement Disorder Society.",
year = "2023",
doi = "10.1002/mds.29311",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
}